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Abstract
Background: Many studies have investigated racial/ethnic disparities in medication non-adherence in patients with
type 2 diabetes using common measures such as medication possession ratio (MPR) or gaps between refills. All
these measures including MPR are quasi-continuous and bounded and their distribution is usually skewed. Analysis
of such measures using traditional regression methods that model mean changes in the dependent variable may
fail to provide a full picture about differential patterns in non-adherence between groups.
Methods: A retrospective cohort of 11,272 veterans with type 2 diabetes was assembled from Veterans
Administration datasets from April 1996 to May 2006. The main outcome measure was MPR with quantile cutoffs
Q1-Q4 taking values of 0.4, 0.6, 0.8 and 0.9. Quantile-regression (QReg) was used to model the association between
MPR and race/ethnicity after adjusting for covariates. Comparison was made with commonly used ordinary-least-
squares (OLS) and generalized linear mixed models (GLMM).
Results: Quantile-regression showed that Non-Hispanic-Black (NHB) had statistically significantly lower MPR
compared to Non-Hispanic-White (NHW) holding all other variables constant across all quantiles with estimates and
p-values given as -3.4% (p = 0.11), -5.4% (p = 0.01), -3.1% (p = 0.001), and -2.00% (p = 0.001) for Q1 to Q4,
respectively. Other racial/ethnic groups had lower adherence than NHW only in the lowest quantile (Q1) of about
-6.3% (p = 0.003). In contrast, OLS and GLMM only showed differences in mean MPR between NHB and NHW
while the mean MPR difference between other racial groups and NHW was not significant.
Conclusion: Quantile regression is recommended for analysis of data that are heterogeneous such that the tails and
the central location of the conditional distributions vary differently with the covariates. QReg provides a comprehensive
view of the relationships between independent and dependent variables (i.e. not just centrally but also in the tails of
the conditional distribution of the dependent variable). Indeed, without performing QReg at different quantiles, an
investigator would have no way of assessing whether a difference in these relationships might exist.
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Background
Diabetes is a chronic debilitating illness that affects
approximately 24 million people in the United States
[1]. Medication adherence is an important component
of good diabetes care and medication non-adherence is
associated with poor glycemic control [2,3], increased
health utilization [4,5], increased health care costs [6,7],
and increased risk of death [5]. African Americans and
other ethnic minority groups have higher prevalence of
diabetes and are at increased risk for poor outcomes
from diabetes [1]. Multiple recent studies have shown
that ethnic minority groups with diabetes have poorer
glycemic, lipid, and blood pressure control compared to
Whites [8]. There are also data that suggest a correla-
tion between ethnic differences in diabetes outcomes
(e.g., glycemic, lipid, and blood pressure control) and
ethnic differences in medication adherence [9]. There-
fore, medication non-adherence is an important risk
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minority groups.
Several methods exist to assess medication adherence
including patient self-report, pill counts, physician/nurse
report, pharmacy refill data, electronic monitoring, and
biological assays [10]. The most commonly used methods
use pharmacy refill data and provide reliable estimates of
medication adherence [10]. Common methods for asses-
sing medication non-adherence with pharmacy refill data
include continuous measure of medication acquisition
(CMA), continuous multiple intervals of oversupply
(CMOS), medication possession ratio (MPR), and medi-
cation refill adherence (MRA), which have all been
shown to be identical in terms of measuring adherence
to prescription refills over a study period [11].
While the literature on ethnic/racial disparities on
medication adherence is scant, some studies using phar-
macy refill data from administrative databases have docu-
mented ethnic differences in medication adherence
among individuals with diabetes [12-14]. However, the
magnitude of these racial/ethnic differences is unclear,
especially across ranges of medication adherence (e.g.
40% vs. 60% vs. 80%). In addition, it is not clear if the
findings of prior studies are reliable given some metho-
dological weaknesses. For example, most prior studies
used traditional regression methods that may not be valid
if certain assumptions are not satisfied. Some studies
used linear regression, which requires the residuals to be
normally distributed and homoscedastic [5,9]. Others
have used logistic regression after categorization of the
outcome [4,12,14], which could lead to arbitrary choice
of categories such that results could be sensitive to choice
of cutoff values. These methods also may not capture the
effect of covariates on the entire distribution of the
response variable.
While both linear and logistic regression focus on differ-
ences in means associated with covariates, quantile regres-
sion allows for studying different directions of the effects
of a covariate on different parts of the distribution (lower
and upper tails, middle part). Furthermore, quantile
regression makes use of the full information of data in
contrast to logistic regression, which is usually associated
with a loss of information due to transformation of the
response MPR into a categorical variable (e.g., binary vari-
able with cutoff at 80%). More importantly, MPR is a
quasi-continuous variable that takes on values that are
bounded (i.e., have lower and/or upper bounds) and hence
traditional methods that use mean changes of the depen-
dent variable with changes in the independent variables
may fail to discern differential patterns in non-adherence
across racial/ethnic groups. Therefore, the aims of this
study were twofold. First, was to examine racial differences
in medication non-adherence using quantile regression.
Second, was to demonstrate through empirical evidence
how choice of a regression method (e.g., QReg, OLS or
GLMM) could result in different conclusions for response
variables like MPR, which usually have skewed distribu-
tions and take on bounded values. We hypothesized that
QReg provides estimates of the effect of covariates on the
conditional quantiles of MPR, leading to a more complete
picture of the differences between race/ethnicity groups
over the entire distribution of MPR including the tails and
center of the conditional distribution.
Methods
We created a cohort of veterans with type 2 diabetes
from a Veterans Administration (VA) facility in the
Southeastern United States using multiple patient and
administrative files from the Veterans Health Adminis-
tration (VHA) Decision Support System (DSS) files
linked by Social Security Number (SSN). The study per-
iod was from April 1996 to May 2006 with an average
follow up period of 5.4 years. The datasets were merged,
cleaned and then used as the final dataset for analysis.
Veterans with type 2 diabetes were identified based on
having at least two ICD-9 codes for diabetes (250.xx) in
either outpatient or inpatient files and having two or
more visits each year since diagnosis based on a pre-
viously validated algorithm [15]. The datasets were
merged to create a subset that only included individuals
with complete adherence data, resulting in a cohort of
11,272 veterans with type 2 diabetes, of which 5,307
were non-Hispanic White (NHW), 3,061 were non-His-
panic Black (NHB), 51 were Hispanic and 1,879 were
identified as Other ethnic/racial group. There were also
974 (8.6%) with missing or unknown race/ethnicity
information. The study was approved by our institu-
tional review board (IRB) and local VA Research and
Development committee.
Outcome Measures
The primary outcome was the mean medication posses-
sion ratio (MPR). MPR informs patient medication
a d h e r e n c eb yp r o v i d i n gt h er a t i oo ft h en u m b e ro fd a y s
of medication supplied within a refill interval to the
number of days in a specified refill interval [16,17]. We
calculated the number of eligible days per medication
within each 90-day refill period per patient. We consid-
ered supply of insulin and oral hypoglycemic agents (VA
classes HS501 and HS502, respectively). The sum of eli-
gible days served as the denominator for the MPR cal-
culation [18]. The average MPR was calculated over the
follow up period from 1996-2006. Prescriptions that
became inactive during that time period did not contri-
bute to the MPR calculation. We chose 90-day intervals
because veterans typically have a 90-day of supply of
medications mailed to their homes. If the MPR exceeded
100%, it was set to 100%.
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The primary covariate of interest was race/ethnicity
classified as NHW, NHB, and Other (including
unknown and missing).
Demographic Variables
We controlled for three demographic variables in addi-
tion to the primary covariate. Age at baseline was trea-
ted as a continuous variable and centered at its mean
value. Marital status was classified as never married,
married (reference category), or separated/widowed/
divorced. Employment was classified as employed, not
employed (reference category), or retired.
Medical Comorbidity
Cancer, congestive heart failure (CHF), coronary heart
disease (CHD), hypertension, and stroke were defined
based on enhanced ICD-9 codes using validated algo-
rithms [19] and coded as 0 or 1 based on presence or
absence of history of the disease at baseline.
Psychiatric Comorbidity
Six psychiatric comorbidities including bipolar disorder,
generalized anxiety disorder, major depressive disorder,
post-traumatic stress disorder, psychotic disorders, and
substance use disorder were defined as present (1) or
absent (0) at baseline based on enhanced ICD-9 codes
using validated algorithms [19].
Statistical analysis
First, we examined the characteristics of the sample
through univariate analysis. This step was followed by
pre-model building analysis, which included testing
whether each covariate was individually associated with
the outcome. To assess whether the relationship
between age and MPR was non-linear, we examined the
significance of a quadratic term for age. Next, a final
model investigating the association between MPR and
race/ethnicity was developed adjusting for all covariates
such as demographics, medical comorbidities, and psy-
chiatric comorbidities.
For quantile regression analysis, the response variable,
MPR, was defined as the quantile of the mean medication
possession ratio for each individual averaged over the
study period. The specifications of the unconditional
quantiles were made in two different ways: Scenario 1) the
quantiles were specified based on clinically meaningful
specific MPR cutoff values: Q1 = 0.40, Q2 = 0.60, Q3 =
0.80, Q4 = 0.90 where the values corresponded to the 2
nd,
4
th,1 5
th and 27
th percentiles of the distribution of MPR
and Scenario 2) the quantiles were based on the distribu-
tion of MPR values where the 5
th,1 0
th,1 5
th,2 5
th and
50
th percentiles were considered. These unconditional
percentiles corresponded to MPR cutoff values of Q1 =
0.66, Q2 = 0.75, Q3 = 0.80, and Q4 = 0.88 and Q5 = 0.97,
respectively.
Quantile regression is used to model the effects of
covariates on the conditional quantiles of a response
variable [20]. This approach is a robust method that
makes no distributional assumption about the error
term in a model. It is also robust to extreme points in
the response space (outliers) but not to extreme points
in the covariate space (leverage points). Confidence
intervals for the estimated parameters in QReg are
based on inversion of a rank test [21,22].
Quantile Regression Model
For a random response variable Y with probability dis-
tribution function F(y) = Prob (Y ≤ y), the τ
th quantile
of Y is defined as the inverse function Q(τ)=i n f{ y:F
(y) ≥ τ}w h e r e0< τ <1 .L e tX=( x 1, ..., xn)d e n o t et h e
matrix consisting of n observed vectors of the random
vector X, and let Y = (y1,. . . ,y n) denote the n observed
responses. The model for linear quantile regression is
given by yi = xibτ + εi,w h e r ebτ =( b1τ,. . . ,bpτ)i st h e
unknown p-dimensional vector of parameters and ε =
(ε1,..., εn) is the n dimensional vector of unknown errors
(Assumption: the τth quantile of εi is zero). The bτ is a
solution of,
min
βτ∈Rp


i∈{i:yixiβτ}
τ

yi − xiβτ

 +

i∈{i:yi<xiβτ}
(1 − τ)

yi − xiβτ



.
The special case τ = 0.5 is equivalent to median
regression. We used the finite smoothing algorithm
[23,24] to compute the solution of this equation so that
the Newton-Raphson algorithm could be used iteratively
to obtain the solution after a finite number of loops.
The regression coefficient at a given quantile (bτ)i n d i -
cates the effect on Y of a unit change in X, assuming
that the other factors are fixed.
Both unadjusted and covariate adjusted models were
fitted with MPR as the response variable and race/ethni-
city as primary variable of interest. Since our sample
size is sufficiently large, the final model was adjusted for
all covariates including demographic variables such as
age, gender, marital status, employment status and med-
ical and psychiatric comorbidities [25]. All models were
assessed for goodness-of-fit using residual analysis. In
addition, QReg was assessed using robust multivariate
location and scale estimates for leverage point detection
[26].
PROC QUANTREG in SAS 9.2 (SAS Institute Inc.,
Cary NC) was used to compute the regression models
and to conduct statistical inferences on the estimated
parameters. Verification for all QReg models was per-
formed using the R [27] quantreg package.
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SAS Proc GLM was used to estimate the parameters of
a multiple regression model where the errors for differ-
ent observations were assumed to be uncorrelated with
identical variances (homoscedastic). Under these
assumptions, OLS provides estimates of the linear para-
meters that are unbiased and have minimum variance
among linear estimators. Residual plots were used to
a s s e s st h e s ea s s u m p t i o n sb u tt h e yd i dn o th o l dt r u ef o r
our data.
Generalized linear Mixed Model (GLMM)
This model extends the above model by allowing a more
flexible specification of the covariance matrix of the
error terms. In other words, it allows for both correla-
tion and heterogeneous variances, although requires
normality assumption [28] which did not hold true for
our data. SAS Proc GLIMMIX was used to estimate the
parameters of a linear mixed model with a random
intercept. This specification allowed different subjects to
have different baseline MPR values. The same sets of
covariates were used in OLS, GLMM and QReg.
Comparison of statistical methods (QReg, OLS, GLMM)
The second aim was addressed using empirical studies
based on re-sampling of the data with replacement. Tra-
ditionally, Monte-Carlo simulation studies based on data
generated from statistical models have been used for
this kind of comparative study. Resampling has the
advantage that the data in resampled datasets are based
on observations from real patients [29] and thus reflect
the appropriate level of diversity and variability found in
realistic populations [30,31]. Sampling with replacement
was used since our dataset can be considered large to
permit numerous samples of reasonable size to obtain
stable conclusions within the smaller samples. Each
dataset in the resampling study consisted of 5,000
patients, which represents many of the typical studies
that use regional VA data. In order to robustly and
accurately estimate the parameters, a total of 10,000
bootstrap replications were performed. The final esti-
mates of the parameters and their standard errors were
obtained using means and standard deviations of the
10,000 parameter estimates. Additionally, we computed
exact percentiles (e.g., 97.5%; 2.5%) for constructing
empirical confidence intervals.
Results
Table 1 shows the socio-demographic characteristics for
the 11,272 veterans with type 2 diabetes included in this
sample. Approximately 97% were male with 47% being
NHW and 27% NHB. The mean age was 66 years. The
most prevalent medical comorbidities were hypertension
(26%), CHD (14%) and CHF (8%). The most prevalent
psychiatric comorbidities were substance use disorder
(14%) and MDD (8%). During the study period the over-
all mortality was 16%. The mean HbA1c value was 7.0%
(sd = 0.9%). Most Veterans (88.4%) had HbA1c values ≤
8.0%. The mean (sd) MPR values for NHW, NHB and
Others were 91.2% (0.2), 88.7% (0.3) and 90.7% (0.3),
respectively. Figure 1, a density plot of MPR by race,
shows the highly skewed nature of the distribution of
MPR by race/ethnicity.
We focus the description of quantile regression results
on Scenario 1 since the results on Scenario 2 were qua-
litatively similar and also because most clinicians are
interested in this scenario. In Figure 2, results compar-
ing quantile regression with ordinary least square (OLS)
regression are shown. While the curves across age for
Table 1 Sample Characteristics by Race and Ethnicity
(n = 11,272)
Race/Ethnicity Category
Variable All NHW NHB Other
Age (years mean, sd) 66 (11.6) 68 (10.7) 64 (12.3) 66 (11.7)
Male 97.3 97.8 96.6 97.2
Female 2.7 2.2 3.4 2.8
Married 65.2 67.2 58.3 68.8
Divorced 28.6 28.1 31.6 26.3
Never Married 6.2 4.7 10.1 4.8
Unemployed 48.2 48.8 53.0 42.0
Retired 30.8 32.7 25.4 33.1
Employed 20.8 18.4 21.6 24.5
Cancer 5.0 5.2 7.5 2.1
CHD 13.9 20.0 12.4 4.6
CHF 8.0 10.0 9.3 3.1
Hypertension 25.7 29.2 33.8 10.7
Stroke 3.0 4.1 3.1 1.0
HbA1c 8+ 11.6 10.0 15.5 10.3
HbA1c (% mean, sd) 7 (0.9) 7 (0.9) 7 (1) 7 (0.9)
Bipolar Disorder 1.9 2.2 2.5 0.6
Generalized Anxiety Disorder 2.2 3.1 1.9 0.7
Major Depressive Disorder 7.8 8.8 10.5 3.0
Post Traumatic Stress
Disorder
5.1 4.6 7.9 3.0
Psychotic Disorder 2.4 1.7 4.9 1.1
Substance Use Disorder 14.4 14.7 21.4 6.4
Dead 16.4 19.0 16.5 11.7
MPR (mean, sd) 90.4
(0.2)
91.2
(0.2)
88.7
(0.3)
90.7 (0.3)
MPR (median, IQR) 97.1 (13) 97.1 (11) 95.0 (16) 100
(11.9)
NHW-non-Hispanic white; NHB-non-Hispanic black;
CHD-coronary heart disease; CHF-congestive heart failure;
HbA1c-glycosolated hemoglobin (%);
MPR-medication possession ratio.
MPR values are reported in percentages.
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ler racial/ethnic differences in mean MPR that decreased
with age, the curves for QReg clearly indicate differences
in MPR across race groups particularly in the lower
quantiles of the MPR distribution. The differences are
more pronounced in the three lower quantiles. The dif-
ference in MPR disappears with higher age in almost all
the quantiles of medication adherence.
In Table 2, the intercept in the first panel is interpreted
as the estimated conditional quantile function of the
MPR distribution of a type 2 diabetes patient who was
f e m a l e ,N H W ,m a r r i e d ,u n e m p l o y e d ,w i t hn oh i s t o r yo f
medical or psychiatric comorbidity and had an average
age of the study population (age = 66 years, since age was
centered at 66). In this adjusted QReg model, NHW had
consistently higher MPR over all quantiles compared to
NHB, and over quantiles 1 and 2 compared to Other
(other racial groups). Compared to NHB, NHW had 3.4%
(p < 0.11) higher MPR in the first quantile (Q1), 5.4%
(p < 0.01) in the second quantile (Q2), 3.1% (p < 0.001)
in the third quantile and 2.0% (p < 0.001) in the fourth
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Figure 1 Distribution of Medication Possession Ratio (MPR) by
Race/Ethnicity (Non-Hispanic White, Non-Hispanic Black, Other
groups). dotted line = Other, dashed line = Non-Hispanic Black,
solid line = Non-Hispanic White.
Figure 2 Distribution of Predicted Mean Medication Possession Ratio (MPR) by age for each type of model (Quantile Regression versus
OLS). OLS = ordinary least squares. Qi = ith quantile (i = 1,.4): Quantiles are based on unconditional MPR cutoff values: 0.4, 0.6, 0.8 and 0.9.
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NHW had 6.3% (p < 0.001) higher MPR in the first quan-
tile (Q1) and 3.8% (p = 0.09) in the second quantile (Q2).
The mean MPR values were also higher for NHW com-
p a r e dt oN H B( 1 . 4 % ,p<0 . 0 0 1 )a ss h o w ni nt h er e s u l t s
for OLS and GLMM. However, the mean MPR difference
between NHW and Other races was not significant
(0.10%, p = 0.74).
On the other hand, in the unadjusted model (see addi-
tional file 1, table S3), compared to NHB, NHW had
16.67% (p < 0.001) higher MPR in the first quantile (Q1),
9.47% (p < 0.001) in the second quantile (Q2), 4.76% (p <
0.001) in the third quantile and 2.63% (p < 0.001) in the
fourth quantile (Q4). Similarly, compared to Other race
groups, NHW had 16.67% (p < 0.001) higher MPR in the
first quantile (Q1) and 8.087% (p = 0.004) in the second
quantile (Q2). The mean MPR values were also higher for
NHW compared to NHB (1.99%, p < 0.001) as shown in
the results for OLS and GLMM. However, the mean MPR
difference between NHW and Other races was not
Table 2 Adjusted parameter estimates (b) and p-values for quantile regression, ordinary least-squares regression, and
the generalized linear mixed model
QReg OLS GLMM
Quantile 1 Quantile 2 Quantile 3 Quantile 4
Parameter b P b P b P b P b P b P
Intercept 38.2 0.00 49.2 0.00 72.1 0.00 82.6 0.00 88.2 0.00 89.5 0.00
NHB -3.42 0.11 -5.42 0.01 -3.1 0.00 -2.0 0.00 -1.4 0.00 -1.3 0.00
Other -6.33 0.00 -3.75 0.09 -0.9 0.34 0.5 0.36 -0.1 0.74 -0.1 0.70
NHW (REF)
Male -11.4 0.04 -7.00 0.22 0.4 0.86 1.1 0.42 -0.5 0.58 -0.4 0.62
Age 0.24 0.01 0.27 0.00 0.2 0.00 0.1 0.00 0.1 0.00 0.1 0.00
Age-squared -0.01 0.14 -0.01 0.04 0.0 0.11 0.0 0.00 0.0 0.00 0.0 0.00
Never Married -2.84 0.45 -7.62 0.05 -0.5 0.79 -1.8 0.06 -0.9 0.16 0.9 0.13
Divorced -3.37 0.09 -5.35 0.01 -2.9 0.00 -2.6 0.00 -1.4 0.00 1.2 0.00
Married (REF)
Employed 5.49 0.02 4.52 0.07 2.8 0.01 1.1 0.06 1.3 0.00 0.6 0.15
Retired -1.03 0.61 2.04 0.34 1.9 0.04 1.3 0.01 0.6 0.06 -0.6 0.04
Unemployed (REF)
Cancer -8.24 0.05 -13.0 0.00 -3.1 0.10 -0.4 0.70 -1.4 0.05 -1.0 0.11
CHD 14.8 0.00 8.2 0.01 0.0 1.00 0.4 0.65 0.7 0.19 0.5 0.31
CHF 1.37 0.71 0.3 0.93 -1.0 0.54 -2.0 0.04 -0.9 0.16 -0.9 0.08
Hypertension 0.46 0.86 -0.5 0.85 -0.8 0.51 -1.6 0.02 -1.1 0.01 -0.9 0.02
Poor HbA1c 12.2 0.00 7.1 0.01 -0.6 0.58 -2.7 0.00 -1.0 0.02 -5.0 0.00
Stroke -1.60 0.75 -4.7 0.37 -0.5 0.81 -0.7 0.58 -0.6 0.47 -0.5 0.47
Bipolar -4.16 0.54 -5.1 0.47 2.3 0.45 -0.6 0.72 -0.2 0.84 0.1 0.93
GAD 1.53 0.79 -1.1 0.86 3.7 0.16 1.6 0.28 0.9 0.36 0.6 0.45
Psychoses 7.28 0.23 6.8 0.28 -3.4 0.21 0.9 0.57 0.0 1.00 -0.5 0.53
PTSD -3.30 0.40 -1.6 0.70 2.6 0.14 1.4 0.18 0.7 0.30 0.9 0.12
Substance Use 7.00 0.01 5.78 0.03 2.6 0.02 1.5 0.02 1.0 0.02 0.8 0.03
NHB = Non-Hispanic Black.
NHW = Non-Hispanic White (Reference).
Other = Other race groups.
b = Parameter Estimate.
P = p-value.
OLS = Ordinary Least Squares.
GLMM = Generalized Linear Mixed Model.
QReg = Quantile Regression.
Quantile 1 = 0.02 corresponding to a medication possession ratio (MPR) of 40%.
Quantile 2 = 0.04 corresponding to a medication possession ratio (MPR) of 60%.
Quantile 3 = 0.15 corresponding to a medication possession ratio (MPR) of 80%.
Quantile 4 = 0.27 corresponding to a medication possession ratio (MPR) of 90%.
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significant quadratic relationship with MPR across all quan-
tiles in the QReg as well as in the OLS and GLMM models.
Divorced veterans had statistically significantly lower MPRs
in quantiles 2, 3 and 4 while single veterans had lower
MPRs in quantiles 2 and 4. Veterans who were employed
had higher MPR compared to unemployed veterans (quan-
tiles 1 and 3), while retired veterans had higher MPRs in
quantiles 3 and 4 compared their unemployed counter-
parts. Veterans with a diagnosis of cancer had lower MPRs
in the first two quantiles while veterans diagnosed with
CHD had higher MPRs in these two quantiles and veterans
with hypertension had lower MPRs in the highest quantile
only compared to their counterparts without these comor-
bidities. Poor HbA1c control was positively associated with
MPR in the first two quantiles (i.e., veterans in poor control
had higher MPR in quantiles 1 and 2) but negatively asso-
ciated with MPR in quantile 4 (i.e., veterans with poor con-
trol had lower MPR). Substance use disorder showed a
statistically significant relationship with MPR in the lowest
and the two highest quantiles but not in the second. In con-
trast, both OLS and GLMM did not show significant differ-
ences by gender, cancer or CHD, missing the significant
differences in the lower tail of the distribution of MPR (Q1
or Q2). Table 3 shows the adjusted model from the boot-
strap studies. The interpretation of the regression coeffi-
cients is similar to those in Table 2 except that these are
values averaged over 10,000 bootstrapped datasets. These
are computed to address concerns with regard to possible
underestimation of the asymptotic standard errors (ASE)
from QReg and to facilitate comparison among the differ-
ent approaches. As expected, the bootstrap standard errors
were larger than the ASEs but the conclusions were qualita-
tively similar (see Table 1). Across all quantiles except the
lowest quantile (Q1), NHB had statistically significantly
lower MPR in the 3
rd and 4
th quantiles compared to NHW
holding all other variables constant. For example, in Q2
NHB had lower MPR compared to NHW with a difference
of -4.5% (95% CI:-10.9%,1.7%). Similarly, the differences
were 3.0% (-2.9%,-5.6%) and -1.9% (-3.3%,-0.54%) in Q3
and Q4, respectively.
An additional set of analyses were performed using the
second set of quantiles determined from the distribution
of MPR or Scenario 2 (see Figure 3 and additional file 1,
additional tables S1, S3a, and S4a). Overall, the results
were qualitatively similar. Additional tables with boot-
strapped based parameter estimates and corresponding
95% CI are reported (see additional file 1, tables S2, S3b,
and S4b).
Discussion
The findings of this study show that the choice of
regression methods in the study of non-normal, semi-
continuous and bounded responses can influence
whether disparities between different racial groups are
uncovered. In this large cohort of Veterans with dia-
betes, differences in the lower tails of the distribution of
MPR by race and comorbidities such as CHD may not
have been discovered using OLS or GLMM methods,
but were identified using quantile regression. While the
regression coefficients of race in both, OLS and GLMM,
only indicate the differences in mean MPR (i.e. covariate
effect in the central portion of the MPR distribution),
the most clinically relevant differences that were found
in the tails of the distribution of MPR (those that are
low or high in adherence) were only detected through
testing of the significance of the regression coefficients
in the lower and upper quantiles of the QReg model.
This study used a large cohort of veterans and appro-
priate statistical methodology permitting a more com-
prehensive assessment of differences in medication non-
adherence by race/ethnicity. Ordinary least squares
regression, logistic regression (after categorization) and
general linear mixed models assume that covariates
affect only the location of the conditional distribution of
the response, and not its scale or any other aspect of its
distributional shape, while quantile regression has the
flexibility for modeling of data with heterogeneous con-
ditional distributions. QReg provides a complete picture
of the covariate effect when a set of percentiles is mod-
eled, and thus offers the capability to capture important
features of the data possibly missed by models that aver-
age over the conditional distribution. One other recent
approach that might be able to capture the effect of cov-
ariates on the entire density of MPR is Bayesian density
regression (BDR) [32,33]. Like QReg, BDR avoids the
assumption of normality and linearity. However, this
approach is not as easy to understand and implement as
QReg. Other approaches include Quasi-likelihood [32],
Box-Cox transformation to normality [33] and robust
regression [34,35]. However, each of these methods has
its own limitations [30].
Research on medication adherence patterns has con-
sistently shown greater non-adherence to anti-hypergly-
cemic agents among NHB with type 2 diabetes
compared to NHW [5,9,12-14]. Consistent with prior
studies, this study found that NHB were more likely to
be medication non-adherent across each of the quan-
tiles. Potential reasons for the difference in medication
adherence by race/ethnicity group have been studied
and seem to suggest that Blacks express more concern
about drug side effects [36], medication dependency,
reduced quality of life [37], and issues related to cost of
medications [7,36,38-40]. For example, among an
insured cohort with pharmacy benefits, an increased
patient cost share of $5/month led to a 15% decrease in
the odds of medication adherence and worsened glyce-
mic control [38]. However, in the VA system where cost
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very low, other factors beyond cost of medications are
likely to explain the observed differences. Potential
explanatory factors that were not available in our dataset
include patient-level factors such as health literacy,
numeracy, self-efficacy, cultural beliefs and attitudes
about medications, and social support. The contribution
of these and other factors need to be explored in future
studies.
Despite the strengths of our data and methodology,
there were limitations that need mentioning. The data-
set did not include information to determine the dura-
tion of diabetes as a way to distinguish between new
and regular users of diabetes medication, thus, we were
not able to assess its impact on medication adherence
rates. However, we created a ‘new users’ group who did
not use medication within the first year of the study and
their proportions were not different from the overall
sample proportion either by race or other demographic
factors (see additional file 1, tables S5). Due to the age
and gender distribution of our sample, our results
should be interpreted with caution in women and
younger aged individuals. In addition, our findings could
have been biased by the 8.6% of veterans with missing
race data. While we believe that the unreported race
information is missing at random, we also performed a
sensitivity analysis via multiple imputation and found
that the results were not different from what is reported
Table 3 Mean parameter estimates (b) with corresponding 2.5% and 97.5% quantiles from a bootstrap study of
10,000 replications with sample size n = 5000
QReg
Quantile1 Quantile2 Quantile3 Quantile4 OLS GLMM
Parameter b (95%CI) b (95%CI) b (95%CI) b (95%CI) b (95%CI) b (95%CI)
Intercept 39.83 (14.7,61.3) 48.8(28.4,69.2) 71.5(60.5,81.5) 82.5(76.4,88.8) 88.23(84.4,91.9) 92.21(88.7,95.2)
NHB -3.54(-11.2,3.43) -4.55(-10.9,1.7) -2.91(-5.6,-0.19) -1.87(-3.3,-0.54) -1.38(-2.31,-0.46) -1.42(-2.10,-0.77)
Other -5.94(-14.4,2.2) -4.38(-13.2,3.1) -1.05(-3.8,1.60) 0.44(-1.2,2.1) -0.12(-1.10,0.85) -0.65(-1.49,0.11)
NHW (REF)
Male -11.8(-22.8,0.39) -6.78(-16.6,3.6) 0.61(-4.9,7.8) 1.13(-3.2,5.5) -0.51(-2.88,2.01) -0.55(-2.50,1.50)
Age 0.24(-0.01,0.55) 0.27(0.01,0.52) 0.17(0.05,0.29) 0.13(0.06,0.19) 0.08(0.03,0.12) 0.04(0.01,0.08)
Age
2 -0.01(-0.02,0.01) -0.01(-0.02,0.01) -0.01(-0.02,0.002) -0.01(-0.01,-0.001) -0.01(-0.01,0.00) -0.01(-0.01,-0.001)
Never Married -3.51(-12.9,6.9) -5.69(-15.9,6.6) -0.76(-5.3,2.9) -2.09(-5.1,0.91) -0.88(-2.71,0.88) -0.83(-0.41,2.12)
Divorced -3.45(-9.7,2.2) -4.67(-10.9,1.2) -3.13(-5.9,-0.57) -2.57(-4.0,-1.1) -1.44(-2.36,-0.56) -0.91(-0.24,1.59)
Married (REF)
Employed 5.10(-1,8,13.1) 4.58(-2.8,11.4) 2.60(-0.17,5.42) 1.16(-4.57,2.9) 1.27(0.20,2.33) 0.08(-0.85,0.97)
Retired -0.06(-6.9,7.8) 1.42(-5.2,7.5) 1.68(-0.91,4.36) 1.22(-0.15,2.6) 0.63(-0.27,1.53) -0.65(-1.35,0.00)
Unemployed (REF)
Cancer -8.20(-19.2,2.7) -11.4(-23.5,1.7) -3.14(-9.9,2.99) -0.45(-3.6,2.2) -1.37(-3.45,0.57) -0.45(-1.89,0.81)
CHD 11.8(0.82,21.2) 8.27(0.94,15.6) 0.65(-2.6,4.32) 0.20(-1.9,2.2) 0.70(-0.64,2.04) -0.14(-1.04,0.79)
CHF 0.68(-10.4,11.2) -0.29(-7.8,7.4) -1.05(-4.7,2.46) -2.05(-4.7,0.28) -0.87(-2.45,0.66) -0.79(-1.93,0.27)
Hypertension (ICD) 1.36(-6.7,11.2) -0.89(-8.6,6.8) -1.30(-4.7,1.54) -1.69(-3.5,0.05) -1.13(-2.33,0.05) -0.09(-0.88,0.67)
Poor HbA1c 10.2(0.5,18.2) 6.45(0.34,12.0) -0.84(-3.6,1.72) -2.59(-4.3,-0.99) -1.00(-2.03,0.02) -4.13(-4.89,-3.34)
Stroke -0.76(-12.3,10.9) -4.04(-13.3,5.9) -1.18(-10.3,4.29) -0.48(-4.2,2.6) -0.60(-2.87,1.55) -0.05(-1.47,1.27)
Bipolar Disorder -3.68(-24.3,19.9) -1.57(-22.7,18.3) 1.49(-4.5,7.1) -0.35(-4.9,3.9) -0.24(-3.35,2.50) -0.31(-1.71,2.06)
GAD 3.89 (-9.5,18.9) 0.50(-14.7,13.2) 2.36(-5.9,7.9) 1.57(-1.5,3.9) 0.88(-1.58,3.12) 0.74(-0.86,2.36)
Psychoses 5.90(-12.0,22.4) 4.72(-12.7, 17.1) -2.38(-8.9,4.6) -0.07(-6.1,3.7) 0.001(-2.7,2.6) -0.65(-2.78,1.23)
PTSD 0.13(-11.7,12.5) -0.75(-13.2, 9.5) 2.30(-3.1,6.5) 1.50(-0.72,3.5) 0.68(-1.01,2.20) 0.58(-0.66,1.86)
Substance Use 5.65(-3.1,15.2) 5.53(-2.5,12.7) 2.90(-0.001,5.7) 1.41(-0.06,2.8) 1.00(-0.01,2.00) 0.26(-0.48,0.99)
NHB = Non-Hispanic Black (Reference = Non-Hispanic White, NHW).
Other = Other race groups.
b = Mean bootstrapped Parameter Estimate.
Quantile 1 = 0.02 corresponding to a medication possession ratio (MPR) of 40%.
Quantile 2 = 0.04 corresponding to a medication possession ratio (MPR) of 60.%.
Quantile 3 = 0.15 corresponding to a medication possession ratio (MPR) of 80.%.
Quantile 4 = 0.27 corresponding to a medication possession ratio (MPR) of 90%.
95% CI = 95% confidence interval based on 2.5% and 97.5% quantiles from a bootstrap study.
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able to skewed and bounded outcomes from cross sec-
tional studies, the message is easily transferable to the
analysis of longitudinal skewed and bounded outcomes
via longitudinal quantile regression.
Conclusions
In conclusion, quantile regression allowed modeling the
differential patterns in medication adherence between
the racial/ethnic groups that would have been missed
using traditional regression methods. QReg is a very use-
ful tool for data that are heterogeneous in the sense that
the tails and the central location of the conditional distri-
butions vary differently with the covariates. Indeed, with-
out performing quantile regression at different quantiles,
an investigator would be unable to assess whether there
might be a difference in these relationships. This method
is also robust as it makes no distributional assumption
about the error term in the model. Future studies need to
be cautious when using traditional regression methods in
modeling quasi-continuous and bounded outcome such
as MPR.
Additional material
Additional file 1: Table S1 Adjusted parameter estimates (b) and p-
values for quantile regression, ordinary least-squares regression,
and the generalized linear mixed model (scenario 2). Table S2.
Adjusted parameter estimates (b) and bootstrapped 95% CI for quantile
regression, ordinary least-squares regression, and generalized linear
mixed model with corresponding 2.5% and 97.5% quantiles from a
bootstrap study of 10,000 replications with sample size n = 5000. Table
S3ab. S3a Title: Unadjusted parameter estimates (b) and p-values for
quantile regression (QReg), ordinary least-squares regression (OLS), and
generalized linear mixed model (GLMM) for the MPR data with sample
size n = 11,272.. S3b Title: Unadjusted parameter estimates (b), and
bootstrapped 95% CI for quantile regression (QReg), ordinary least-
squares regression, and generalized linear mixed model with
corresponding 2.5% and 97.5% quantiles from a bootstrap study of
10,000 replications with sample size n = 5000. Table S4ab. S4a Title:
Unadjusted parameter estimates (b) and p-values for quantile regression
(QReg), ordinary least-squares regression (OLS), and generalized linear
mixed model (GLMM) for the MPR data with sample size n = 11,272.. S4b
Title: Unadjusted parameter estimates (b), and bootstrapped 95% CI for
quantile regression (QReg), ordinary least-squares regression, and
Figure 3 Distribution of Predicted Mean Medication Possession Ratio (MPR) by age for each type of model (Quantile Regression
versus OLS). OLS = ordinary least squares. Qi = ith quantile (i = 1,.5): Quantiles are based on unconditional MPR cutoff values: 0.33, 0.48, 0.61
0.72 and 0.94.
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Page 9 of 11generalized linear mixed model with corresponding 2.5% and 97.5%
quantiles from a bootstrap study of 10,000 replications with sample size
n = 5000. Table S5. Comparison of the proportion of new medication
users by demographic variables with the overall proportion in the study
sample (washout analysis)
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